PINC Research neutral on pharma space

PINC Research has come out with its report on pharma space.

• Alchemia expects DRL to have 30-34% market share in generic Arixtra which was launched in July 2011.
• Post the launch of authorised generic, Alchemia will now share 50% of operating profit (from earlier 60%) as pricing discount would rise.
• Alchemia will reimburse certain (could be between USD5-9mn) amount of development expenses to DRL in next few months.
• Apicore and Reliable have filed DMF for generic Arixtra. Alchemia is confident that they will take at-least 2-3years to come to the market.

Read More